Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The importance of dopamine D2 receptors (DRD2) for central nervous dopaminergic signalling makes variants in the DRD2 gene potential modulators of the risk or course of various behavioural, psychiatric or neurologic diseases (e.g. addiction, schizophrenia, Parkinson's disease).
|
19512960 |
2009 |
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients.
|
19396436 |
2009 |
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
This study identified apomorphine use and levodopa dosages between 500 and 1000 mg as non-genetic and the 15× DRD2 CA repeat allele as genetic determinants for the discontinuation of non-ergoline DA treatment in patients with PD.
|
19669131 |
2009 |
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Among non-Hispanic whites, homozygous carriers of Taq1A DRD2 (rs1800497) polymorphism had an increased risk of PD compared to homozygous wildtype carriers (OR=1.5, 95% CI 1.0-2.3).
|
21663922 |
2011 |
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The DRD2 rs1800497 and DRD4 rs1800955 polymorphisms showed no association with PD.
|
21781348 |
2011 |
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Since genetic factors could play a role in determining the occurrence of these problems, the aim of the present study was to investigate whether possible functional polymorphisms among DRD2 and ANKK1 genes are associated with the risk of developing dyskinesia and motor fluctuations in Parkinson's disease patients.
|
23171335 |
2012 |
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We assessed whether allelic variants of dopamine D2 receptors (DRD2), catechol-O-methyltransferase (COMT) and dopamine transporter (DAT) were associated with the development of ICDs in PD.
|
22113132 |
2012 |
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Antipsychotics and serotoninergic antidepressants may potentially attenuate PD risk, and lithium and bupropion may augment risk, through MAPT, GBA, CCDC62, HIP1R, BDNF, and DRD2 transcription, with MAPT, GBA, and CCDC62 being strongly associated with PD risk in recent meta-analyses.
|
22507762 |
2012 |
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In the current study, we determined whether a dopamine D2 receptor DNA sequence polymorphism interacts with L-DOPA during motor tasks in patients with Parkinson's disease (PD).
|
23439215 |
2013 |
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We examined the relation between inhibitory ability (measured by the Stop Signal Task) and polymorphisms of COMT Val158Met and DRD2 C957T in patients with idiopathic PD.
|
24749760 |
2014 |
Parkinson Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Pharmacological modulation of A2ARs is particularly useful in Parkinson's disease (PD) due to their property of antagonizing dopamine D2 receptor activity.
|
24892887 |
2014 |
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The DRD3 (rs6280) polymorphism, but not DRD2 (Taq1A) or GRIN2B, influences younger PD age of onset in the US Caucasian population.
|
26627941 |
2016 |
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Single nucleotide polymorphisms, rs2283265 and rs1076560, in the dopamine D2 receptor gene (DRD2) were found to be significantly associated with a favourable peak response to rasagiline at 12 weeks in early Parkinson's disease after controlling for multiple testing.
|
27190009 |
2016 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
In conclusion, we suggest that L-DOPA may attenuate the neuropathology of PD by regulating signaling related to DRD2 in neuronal cells under α-syn-induced toxicity.
|
28687316 |
2017 |
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
To investigate the association between Dopamine receptor D type 2 (DRD2) dinucleotide short tandem repeat (CA<sub>n</sub>-STR) and Dopamine receptor D type 3 (DRD3) Ser9Gly polymorphisms and the risk of PD, as well as the possible reasons for PD patients using different doses of DAs, we recruited 168 idiopathic PD patients and 182 controls.
|
27817855 |
2017 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate the topographical distribution of dopamine transporter (DAT), dopamine D2 receptor, and glucose metabolism in Parkinson's disease (PD) using PET/computed tomography (CT) scanning and statistical parametric mapping (SPM) analysis.
|
27893588 |
2017 |
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Human genetic studies also show a significant association of DRD2 polymorphisms with disorders including schizophrenia and Parkinson's disease.
|
29107444 |
2017 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
The changes in expression at the mRNA and protein levels suggest that Snca may be involved in neurodegeneration and Drd2 may participate in the development of the compensatory mechanisms in the early stages of PD pathogenesis.
|
27757834 |
2017 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
The D2 dopamine receptor (DRD2) is the primary target for both typical and atypical antipsychotic drugs, and for drugs used to treat Parkinson's disease.
|
29466326 |
2018 |
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease.
|
29434188 |
2018 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
In the present study, we used 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced PD mouse model to investigate whether Drd2 could suppress astrocytic NLRP3 inflammasome activation.
|
29786071 |
2018 |
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The poorer cognitive performance in DRD2 <sup>957</sup> T/T carriers with PD occurred mainly in episodic memory and attention.
|
28869277 |
2018 |
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
To determine whether dopaminergic (rs1076560 DRD2 G > T and rs4680 catechole-o-methyltranspherase (COMT) Val158Met) or brain derived neurotrophic factor (rs6265 BDNF Val66Met) genetic polymorphisms are associated with gait function and medication responsiveness in Parkinson's disease.
|
29249680 |
2018 |
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease.
|
29908325 |
2018 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our study illustrates that astrocytic Drd2 inhibits neuroinflammation through a β-arrestin2-dependent mechanism and provides a new strategy for treatment of PD.
|
30200997 |
2018 |